A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Clinical trial NCT03899805 · COMPLETED

Trial details

NCT number: NCT03899805
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Sarcoma Liposarcoma Leiomyosarcoma Undifferentiated Pleomorphic Sarcoma

Start date: 2019-06-04
Primary completion: 2024-07-16
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.